So Centene's Q4 numbers came in not long ago, and honestly, the story here is pretty interesting if you're following healthcare stocks. The company had some real headwinds going into this quarter - membership pressures and elevated medical costs that the whole sector's been dealing with.

Here's what stood out to me. Revenue-wise, they managed around $48 billion for the quarter, which showed solid 18% year-over-year growth. That's the kind of top-line number that usually looks decent on paper. But the bottom line tells a different story - they posted a loss of about $1.25 per share, down massively from the year before. The question everyone was asking is whether they could escape the negative narrative around rising medical costs and membership headwinds that have been haunting the sector.

The membership picture was mixed. Commercial memberships grew nearly 30% thanks to marketplace gains, which is solid. Medicare PDP memberships also climbed about 15%. But here's the catch - total membership actually declined 2.4% year-over-year because Medicaid and Medicare segments both shrank. That's the kind of contradiction that makes these healthcare plays tricky right now.

What really hurt the bottom line was the medical cost situation. The health benefits ratio came in at 93.7%, way up from 89.6% a year prior. For those not tracking this closely, that means less premium money staying on the balance sheet after claims get paid. Service revenues also dipped about 2.6%, and investment income fell slightly.

Comparing this to peers gives some context. UnitedHealth managed to beat estimates despite similar pressures, posting $2.11 adjusted EPS versus the $2.09 consensus. Elevance Health actually impressed, beating by over 7% with strong premium growth and Medicare Advantage momentum. Both companies showed that while the headwinds are real, execution matters.

The real question for Centene going forward is whether they can escape these cost and membership pressures that seem structural right now. The consensus had them pegged at an Earnings ESP of 0%, which basically meant no one was predicting a surprise either way. With the whole healthcare sector wrestling with elevated medical costs, this is one to keep watching.